NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 14 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Q2 FY27 முடிவுகள்: விற்பனை ₹1,145 கோடி, மாற்றமில்லை; PAT 7% YoY சரிந்து ₹196 கோடி
Procter & Gamble Hygiene and Health Care Ltd. (PGHH) செப்டம்பர் 30, 2026 உடன் முடிந்த காலாண்டுக்கான நிதி முடிவுகளை அறிவித்தது. விற்பனை ஆண்டுக்கு ஆண்டு (YoY) மாற்றமின்றி ₹1,145 கோடியாக இருந்தது. Profit After Tax (PAT) 7% YoY சரிந்து ₹196 கோடியானது. மூலப்பொருள், எரிசக்தி செலவு உயர்வு, கமாடிட்டி ஏற்ற இறக்கம் மற்றும் பாதகமான அந்நியச் செலாவணி விகிதங்கள் இரட்டை இலக்க அழுத்தத்தை ஏற்படுத்தின. உற்பத்தித் திறன் திட்டங்கள் செலவு உயர்வின் ஒரு பகுதியை ஈடுகட்டின; அதே நேரத்தில் நிறுவனம் விளம்பரம் மற்றும் விளம்பரச் செலவுகளைத் (A&P) தொடர்ந்தது. H1 FY27-இல் மேம்படுத்தப்பட்ட Vicks ZzzQuil with Ashwagandha மற்றும் Vicks medicated lozenges அறிமுகப்படுத்தப்பட்டன.
உச்சம் நம்பிக்கை
என்ன மாறியதுPGHH தனது Q2 முடிவுகள் குறித்த செய்திக்குறிப்பை வெளியிட்டது; அதில் மாற்றமில்லாத வருவாயும், மூலப்பொருள் செலவு அழுத்தம் மற்றும் அதிகரித்த A&P முதலீடுகளால் நிகர லாபத்தில் 7% சரிவும் காணப்பட்டது.
ஏன் இது முக்கியம்உற்பத்தித் திறன் திட்டங்கள் இருந்தும், கமாடிட்டி செலவுகள் மற்றும் நாணய ஏற்ற இறக்கங்களால் லாப வரம்பு தொடர்ந்து அழுத்தத்தில் உள்ளது என்பதை இது காட்டுகிறது. இதனால் முக்கிய நுகர்வோர் ஆரோக்கியம் மற்றும் சுகாதாரப் பிரிவுகளில் கீழ்நிலை லாப வளர்ச்சி தடைபடுகிறது.
காலாண்டு விற்பனை: ₹ 1145 கோடிProfit After Tax (PAT): ₹196 கோடிPAT ஆண்டு மாற்றம் (YoY): -7%விற்பனை ஆண்டு மாற்றம் (YoY): மாற்றமில்லை
📅 குறுகிய காலம்பலவீனமான வருவாய் முடிவுகளும், தட்டையான மொத்த விற்பனை வளர்ச்சியும், சமீபத்திய மாதங்களில் தொடரும் பங்கு விலை பின்தங்கலுடன் சேர்ந்து, சந்தை உணர்வை பாதிக்கலாம்.
📈 நீண்ட காலம்நீண்டகாலப் பாதை, பெண்கள் சுகாதாரப் பிரிவில் (Whisper) மற்றும் ஆரோக்கியப் பிரிவில் (Vicks) வகை ஊடுருவல், அத்துடன் தொடரும் உற்பத்தித் திறன் திட்டங்களின் செயல்திறனைப் பொறுத்தது.
⚠ அபாய எச்சரிக்கைகள்
மூலப்பொருள் மற்றும் எரிசக்தி செலவு ஏற்ற இறக்கம்
பாதகமான அந்நியச் செலாவணி ஏற்ற இறக்கங்கள்
தேக்கமடைந்த மொத்த விற்பனை வளர்ச்சி
👀 கவனிக்க வேண்டியவை
கமாடிட்டி செலவு குறையும்போது, Whisper மற்றும் Vicks தயாரிப்பு வரிசைகளில் மொத்த லாப வரம்பு மீட்சி மற்றும் வால்யூம் விரிவாக்கத்தின் அறிகுறிகளுக்காக அடுத்தடுத்த காலாண்டுகளைக் கண்காணியுங்கள்.
PGHH Denies Market Rumours of Delisting and Winding Up Operations
Procter & Gamble Hygiene and Health Care Limited (PGHH) issued a clarification under Regulation 30(11) following material price movements. The company categorically denied market rumours regarding a potential delisting or winding up of its operations, labeling them as baseless. This comes amid a steep 46.0% drop in share price over the past 12 months, despite stable promoter shareholding at 70.64%. The company affirmed that any price-sensitive information will be formally communicated via regulatory disclosures.
உச்சம் நம்பிக்கை
என்ன மாறியதுPGHH has formally clarified and denied persistent market rumours about delisting or operational winding down.
ஏன் இது முக்கியம்Dispels extreme downside speculation that may have contributed to severe share price volatility and the stock's 46% decline over the past year.
📅 குறுகிய காலம்May help curtail speculative selling driven by delisting/closure rumours over the next few sessions.
📈 நீண்ட காலம்Limited; fundamental performance in feminine care and healthcare, alongside margin resilience, remains the primary driver.
⚠ அபாய எச்சரிக்கைகள்
Elevated market volatility driven by unsubstantiated market rumours
👀 கவனிக்க வேண்டியவை
Track trading volumes and price stability following the clarification, along with upcoming quarterly earnings disclosures to evaluate core business health.
₹901 Cr Sales: PGHH Reports 5% Revenue Decline and PAT Compression in June 2026 Quarter
Procter & Gamble Hygiene and Health Care (PGHH) reported a 5% year-on-year decline in sales to ₹901 crores for the quarter ended June 30, 2026. Profit After Tax (PAT) came in at ₹126 crores, a sharp decline from the ₹192.06 crores reported in the same quarter last year. The company cited commodity cost fluctuations driven by geopolitical uncertainties and a deliberate increase in advertising and promotional (A&P) spending as primary reasons for the margin pressure. Despite the slowdown, the company continues to focus on its 'Integrated Growth Strategy' and product superiority in the feminine hygiene and healthcare segments.
உச்சம் நம்பிக்கை
என்ன மாறியதுPGHH experienced a contraction in both top-line revenue and bottom-line profitability for the quarter ended June 30, 2026, compared to the previous year.
ஏன் இது முக்கியம்The results reflect a challenging operating environment where cost inflation and the need for higher marketing support are squeezing margins for even high-ROCE multinational brands.
📅 குறுகிய காலம்The stock may face downward pressure in the short term as the market reacts to the decline in both revenue and PAT compared to the previous year.
📈 நீண்ட காலம்While the current quarter is weak, the company's structural moat remains strong due to its market-leading brands (Whisper, Vicks) and high capital efficiency, though growth has moderated to the mid-single digits.
👀 கவனிக்க வேண்டியவை
Investors should monitor whether the increased advertising spend translates into volume growth in subsequent quarters and watch for any stabilization in raw material costs. The focus remains on the recovery of urban demand and the performance of premium launches like Whisper Period Pants.
PGHH Q4 Net Profit Drops 34.3% YoY to ₹126.27 Cr; Revenue Declines 4.9%
Procter & Gamble Hygiene and Health Care (PGHH) reported a weak set of results for the quarter ended June 30, 2026. Revenue from operations declined 4.9% YoY to ₹891.46 Cr, while Net Profit saw a sharp contraction of 34.3% YoY to ₹126.27 Cr. The bottom line was significantly impacted by a 21.2% increase in advertising and sales promotion expenses, which rose to ₹83.32 Cr despite falling sales. Profit Before Tax (PBT) also fell sharply by 35.9% YoY to ₹169.63 Cr, indicating substantial margin pressure.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company experienced a simultaneous decline in both top-line and bottom-line performance, with a notable spike in marketing costs failing to drive revenue growth.
ஏன் இது முக்கியம்The sharp drop in profitability for a high-ROCE (157%) company suggests either intense competitive pressure in the feminine hygiene/healthcare segments or a significant slowdown in consumer off-take for premium products.
Revenue (Jun 2026): ₹891.46 கோடிNet Profit (Jun 2026): ₹126.27 கோடிYoY Revenue Growth: -4.9%YoY Net Profit Growth: -34.3%Ad Spend as % of Revenue: 9.35%
📅 குறுகிய காலம்The stock is likely to face downward pressure in the short term due to the significant earnings miss and margin contraction.
📈 நீண்ட காலம்While the company maintains a strong brand moat with Whisper and Vicks, the structural growth rate and ability to pass on cost inflation/marketing costs will be key to restoring its premium valuation.
⚠ அபாய எச்சரிக்கைகள்
Significant margin compression
Negative revenue growth
Rising advertising costs relative to sales
👀 கவனிக்க வேண்டியவை
Investors should monitor management commentary regarding the effectiveness of increased advertising spends and the trajectory of rural demand recovery, as the current results show significant margin erosion.
PGHH Appoints Gopalakrishnan Kalianna as Sales Head Effective August 1, 2026
Procter & Gamble Hygiene and Health Care Limited (PGHH) has appointed Mr. Gopalakrishnan Kalianna as Sales Head, effective August 1, 2026. He succeeds Ms. Rohini Venkateswaran, who is being elevated to a global role as Senior Vice President-Korea. Mr. Kalianna is a P&G veteran with over 20 years of experience, previously leading India's Go-To-Market strategy and Fabric Care sales. This transition occurs as the company maintains a strong financial profile with a Dec 2025 quarterly revenue of ₹1,261.9 cr and a high ROCE of 157%.
உச்சம் நம்பிக்கை
என்ன மாறியதுA leadership transition in the sales function, moving from Ms. Rohini Venkateswaran to Mr. Gopalakrishnan Kalianna.
ஏன் இது முக்கியம்Sales leadership is vital for PGHH to maintain its market-leading positions in feminine hygiene (Whisper) and healthcare (Vicks), especially as it targets 'personalized availability' through quick-commerce.
Effective Date: ஆகஸ்ட் 1, 2026Experience of New Sales Head: 2+ decadesDec 2025 Quarterly Revenue: ₹1,261.9 கோடிROCE: 157.0%Promoter Holding: 70.64%
📅 குறுகிய காலம்The announcement is unlikely to impact the stock price in the short term as it represents a planned internal succession within the P&G group.
📈 நீண்ட காலம்Limited structural impact; P&G's robust internal talent pipeline typically ensures continuity in business strategy and operational excellence.
👀 கவனிக்க வேண்டியவை
Investors should monitor the execution of the company's 'Integrated Growth Strategy' under new sales leadership, particularly in high-growth segments like e-commerce and rural recovery.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
PGHH Declares ₹60 Final Dividend for FY 2025-26; Issues TDS Guidelines for Shareholders
Procter & Gamble Hygiene and Health Care Limited (PGHH) has declared a final dividend of ₹60 per equity share for the financial year 2025-26. The company has issued a detailed communication regarding Tax Deducted at Source (TDS) on this dividend income, noting a standard 10% rate for resident shareholders with a valid PAN. Shareholders must submit relevant tax exemption forms or DTAA documents to the Registrar (MUFG Intime India) by August 14, 2026, to ensure appropriate tax treatment. The dividend is subject to approval at the upcoming Annual General Meeting.
முக்கிய அம்சங்கள்
Final dividend of ₹60 per equity share of face value ₹10 declared for FY 2025-26.Standard TDS rate of 10% for resident shareholders with valid PAN; 20% for invalid or missing PAN.No TDS for resident individual shareholders if the total dividend amount does not exceed ₹10,000 in the fiscal year.Non-resident shareholders can avail lower DTAA rates by submitting Tax Residency Certificates and Form 41.Deadline for submitting tax-related declarations and documents to the RTA is August 14, 2026.
👀 கவனிக்க வேண்டியவை
Shareholders should verify that their PAN is linked with Aadhaar and submit Form 121 or relevant DTAA documents to the RTA before August 14 to avoid higher tax withholding.
PGHH FY26 Results: PAT Grows 19% to ₹850 Cr Despite Flat Sales of ₹4,300 Cr
Procter & Gamble Hygiene and Health Care Limited (PGHH) reported flat sales of ₹4,300 crores for the fiscal year ended March 31, 2026. Despite the stagnant top-line growth, the company achieved a 19% increase in Profit After Tax (PAT) to ₹850 crores, driven by aggressive productivity and cost-saving programs. Management is doubling down on its 'integrated growth strategy' focusing on product superiority and premiumization in the Feminine Care and Personal Healthcare segments to navigate a high-inflation and fragmented media environment.
முக்கிய அம்சங்கள்
Reported annual sales of ₹4,300 crores, remaining flat year-on-year due to a challenging operating environment.Achieved a 19% growth in Profit After Tax (PAT) to ₹850 crores through targeted savings programs.Upgraded Vicks ZzzQuil Natura with a higher 5mg melatonin dosage and 50mg natural ashwagandha.Expanded the Feminine Care portfolio with Whisper Period Panties and an upgraded Whisper Nights range.Management identified quick commerce and agentic AI as transformative shifts in the current retail landscape.
👀 கவனிக்க வேண்டியவை
Investors should focus on the company's ability to maintain high margins through productivity gains despite flat revenue growth. Monitor the adoption of premium products like Period Panties and ZzzQuil as indicators of successful brand premiumization in a value-conscious market.
PGHH Appoints Mohit Pradhan as VP and Category Leader for Feminine Hygiene Business
Procter & Gamble Hygiene and Health Care Limited (PGHH) has announced the appointment of Mr. Mohit Pradhan as Vice President and Category Leader for its Feminine Hygiene Business, effective August 1, 2026. Mr. Pradhan, an IIM Ahmedabad alumnus with 20 years of experience at P&G, succeeds Mr. Girish Kalyanaraman, who will transition to a new role within the P&G group after June 30, 2026. This leadership change is significant as the Feminine Hygiene segment is a core business driver for the company. Mr. Pradhan previously served as VP and General Manager for P&G Indonesia, bringing extensive international experience in general management and commercial strategy.
முக்கிய அம்சங்கள்
Mr. Mohit Pradhan appointed as VP and Category Leader for Feminine Hygiene Business effective August 1, 2026.Outgoing leader Mr. Girish Kalyanaraman to exit the senior management team on June 30, 2026, for a new P&G assignment.Mr. Pradhan brings 20 years of experience at P&G, including a recent stint as VP and GM for P&G Indonesia.The appointee holds an MBA from IIM Ahmedabad and an engineering degree from the Marine Engineering & Research Institute Kolkata.
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine leadership transition within the P&G ecosystem. No immediate action is required, though monitoring the performance of the Feminine Hygiene segment under the new leadership is advised.
PGHH FY26 PAT Up 19% to ₹857 Cr; Total Dividend Declared at ₹255 Per Share
Procter & Gamble Hygiene and Health Care Limited (PGHH) reported a 19% increase in Profit After Tax (PAT) to ₹857 crore for FY26, despite flat annual sales of ₹4,290 crore. The growth in profitability was primarily driven by a better product mix and operational efficiencies. However, the fourth quarter showed signs of a slowdown, with sales declining 5% to ₹941 crore and PAT falling 2% to ₹153 crore. A significant highlight for shareholders is the total dividend payout of ₹255 per share for the fiscal year, including a newly recommended final dividend of ₹60.
முக்கிய அம்சங்கள்
Annual Profit After Tax (PAT) rose 19% to ₹857 crore for the fiscal year ended March 31, 2026.Full-year sales remained stagnant at ₹4,290 crore compared to the previous 12-month period.Q4 sales and PAT declined by 5% and 2% respectively, indicating a challenging quarter.Total dividend for the year reached ₹255 per share, including a final dividend of ₹60.Profitability gains were attributed to product mix and productivity rather than top-line growth.
👀 கவனிக்க வேண்டியவை
Investors should focus on the high dividend yield and margin resilience but remain cautious about the stagnant revenue growth and Q4 decline. The stock remains a solid defensive pick for income-seeking investors, though volume growth needs to be monitored.
PGHH Appoints Srividya Srinivasan as CFO; Gaurav Bhartia to Step Down Effective June 30, 2026
Procter & Gamble Hygiene and Health Care Limited (PGHH) has announced a significant leadership transition effective July 1, 2026. Mr. Gaurav Bhartia will resign as CFO to take up a new assignment within the global P&G group, and will be replaced by Ms. Srividya Srinivasan, who brings 20 years of finance experience. Additionally, Mr. Ghanashyam Hegde will transition from his role as Company Secretary to a Non-Executive Director, ensuring continuity on the board. These changes appear to be part of P&G's standard internal talent rotation strategy.
முக்கிய அம்சங்கள்
Ms. Srividya Srinivasan appointed as Executive Director and CFO for a 5-year term starting July 1, 2026.Current CFO Gaurav Bhartia to step down on June 30, 2026, to pursue a different assignment within P&G.Mr. Ghanashyam Hegde re-designated as Non-Executive Director effective July 1, 2026, after resigning as Company Secretary.Incoming CFO Srividya Srinivasan has 20 years of experience across P&G markets including USA, Latin America, and Philippines.
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine management rotation typical of multinational corporations; no immediate action is required as the transition period is well-defined.
PGHH Appoints Srividya Srinivasan as CFO; Ghanashyam Hegde Re-designated as Non-Executive Director
Procter & Gamble Hygiene and Health Care Limited (PGHH) has announced a significant leadership transition effective July 1, 2026. Ms. Srividya Srinivasan, a P&G veteran with 20 years of global experience, has been appointed as the new Chief Financial Officer and Executive Director for a five-year term. She succeeds Mr. Gaurav Bhartia, who is moving to a new assignment within the P&G group. Additionally, Mr. Ghanashyam Hegde will transition from his role as Company Secretary to a Non-Executive Director position on the board.
முக்கிய அம்சங்கள்
Ms. Srividya Srinivasan appointed as CFO and Executive Director for a 5-year term starting July 1, 2026.Outgoing CFO Gaurav Bhartia to resign effective June 30, 2026, to take up a new assignment within P&G.Mr. Ghanashyam Hegde re-designated as Non-Executive Director effective July 1, 2026, while moving to a regional VP role.New CFO Srividya Srinivasan brings 20 years of finance experience across markets including USA, Latin America, and Philippines.
👀 கவனிக்க வேண்டியவை
Investors should view this as a routine leadership rotation typical of multinational corporations; no immediate action is required as the transition appears well-planned for July 2026.
PGHH Recommends Final Dividend of ₹60 per Share; FY26 PAT at ₹856.5 Crore
Procter & Gamble Hygiene and Health Care Limited (PGHH) has recommended a final dividend of ₹60 per equity share for the financial year ended March 31, 2026. The company reported a Profit After Tax (PAT) of ₹856.5 crore for the full year, with an EPS of ₹263.86. Annual revenue from operations stood at ₹4,290.4 crore. Investors should note that the previous financial year was a nine-month period, making direct year-on-year comparisons complex, though the company maintains a strong cash position of ₹557 crore.
முக்கிய அம்சங்கள்
Recommended a final dividend of ₹60 per equity share (600% of face value) for FY 2025-26.Reported annual revenue from operations of ₹4,29,042 Lakhs (₹4,290.4 Crore).Net Profit for the year reached ₹85,650 Lakhs (₹856.5 Crore) with a Basic EPS of ₹263.86.The dividend is scheduled for payment on or before September 18, 2026, subject to shareholder approval.Cash and cash equivalents increased to ₹55,702 Lakhs from ₹46,637 Lakhs in the previous period.
👀 கவனிக்க வேண்டியவை
Investors should consider holding the stock for its consistent dividend payout and strong balance sheet. Monitor the upcoming Annual General Meeting for the final approval and the announcement of the record date for dividend eligibility.
PGHH Sets August 17, 2026, as Record Date for Dividend and 62nd AGM
Procter & Gamble Hygiene and Health Care Limited (PGHH) has announced August 17, 2026, as the record date for its upcoming dividend and 62nd Annual General Meeting (AGM). The AGM is scheduled to take place on August 24, 2026. Shareholders appearing in the register on the record date will be eligible for the dividend payout, provided it is approved by members during the meeting. This follows the company's standard corporate governance cycle for its June-ending fiscal year.
முக்கிய அம்சங்கள்
Record date for dividend eligibility and 62nd AGM participation is August 17, 2026.The 62nd Annual General Meeting is scheduled to be held on August 24, 2026.Dividend payment is contingent upon shareholder approval at the ensuing AGM.The official notification was issued to BSE and NSE on May 28, 2026.
👀 கவனிக்க வேண்டியவை
Investors interested in the dividend should ensure they own the shares before the ex-dividend date (typically one business day prior to the record date). Monitor for the specific dividend amount if not already noted from the preceding earnings announcement.
PGHH Declares ₹195 Interim Dividend Including ₹25 Special Dividend for FY 2025-26
Procter & Gamble Hygiene and Health Care Limited (PGHH) has declared a substantial interim dividend of ₹195 per equity share for the financial year 2025-26. This total payout includes a one-time special dividend of ₹25 per share on a face value of ₹10. The company has set February 5, 2026, as the record date to determine shareholder eligibility for the payout. Detailed tax deduction at source (TDS) guidelines have been issued, requiring shareholders to submit necessary documentation by February 2, 2026.
முக்கிய அம்சங்கள்
Interim dividend of ₹195 per equity share declared, including a ₹25 special dividend.Record date for dividend entitlement is fixed as February 5, 2026.Standard TDS of 10% for resident shareholders with PAN and 20% for those without.Non-resident shareholders can avail DTAA benefits by submitting Form 10F and TRC.Deadline for submission of tax-related documents is February 2, 2026, at 5 PM.
👀 கவனிக்க வேண்டியவை
Investors should ensure their PAN and bank account details are updated with their Depository Participant or RTA before the record date. Eligible shareholders should submit Form 15G/15H or other tax-exempt documents by February 2 to avoid higher TDS.
PGHH Q3 PAT Rises 12% to ₹301 Cr; Declares ₹195 Interim Dividend
Procter & Gamble Hygiene and Health Care (PGHH) reported a modest 1% YoY increase in sales to ₹1262 crore for the quarter ended December 31, 2025. Despite the slow top-line growth, Profit After Tax (PAT) surged by 12% to ₹301 crore, driven by operational efficiencies and a favorable product price-mix. A significant highlight for shareholders is the declaration of an interim dividend of ₹195 per share, which includes a ₹25 special dividend. The company continues to focus on its core brands like Whisper and Vicks through an integrated growth strategy.
முக்கிய அம்சங்கள்
Sales for the quarter ended December 31, 2025, stood at ₹1262 crore, up 1% YoY.Profit After Tax (PAT) increased by 12% YoY to reach ₹301 crore.Declared a total interim dividend of ₹195 per equity share for FY 2025-26.Dividend includes a one-time special dividend of ₹25 per equity share.Profitability growth attributed to operational efficiencies and favorable product price-mix.
👀 கவனிக்க வேண்டியவை
Investors should find the high dividend payout and margin expansion attractive, though the 1% sales growth suggests a need to monitor volume recovery. The stock remains a strong defensive pick for income-seeking investors due to its robust cash flow and brand leadership.
PGHH appoints Tushar Gupta as Category Leader- Health Care, effective Jan 1, 2026
Procter & Gamble Hygiene and Health Care Limited announced the appointment of Mr. Tushar Gupta as the Category Leader- Health Care, effective January 1, 2026. Ms. Maithreyi Jagannathan will be leaving the company on December 31, 2025. Mr. Gupta previously served as a Brand Manager on Vicks in India and later led design for Asia, Middle East & Africa in Singapore. He currently leads brand design and communication for Vicks and Zzzquil for the APAC region as a Senior Director.
முக்கிய அம்சங்கள்
Tushar Gupta appointed as Category Leader- Health Care effective January 1, 2026Maithreyi Jagannathan to leave the company effective December 31, 2025Tushar Gupta is an alumnus from IIM Calcutta and an engineer from Manipal Institute of TechnologyTushar Gupta previously led brand design for Asia, Middle East & Africa in Singapore
👀 கவனிக்க வேண்டியவை
This is a management change, so monitor the company's performance in the health care segment under the new leadership. Review future earnings reports to assess the impact of this change.
PGHH: Maithreyi Jagannathan to cease as Category Leader- Health Care on Dec 31, 2025
Procter & Gamble Hygiene and Health Care Limited announced that Ms. Maithreyi Jagannathan will cease to be the Category Leader, Health Care, effective December 31, 2025, as she is leaving the company. Mr. Tushar Gupta will take over as Category Leader- Health Care effective January 1, 2026. Mr. Gupta previously served as a Brand Manager on Vicks India and currently leads brand design and communication for Vicks and Zzzquil for the APAC region as a Senior Director.
முக்கிய அம்சங்கள்
Ms. Maithreyi Jagannathan ceases to be Category leader, Health Care effective December 31, 2025.Mr. Tushar Gupta will take over as Category leader- Health Care effective January 1, 2026.Mr. Gupta is an alumnus from IIM Calcutta and an engineer from Manipal Institute of Technology.Mr. Gupta currently leads brand design and communication for Vicks and Zzzquil for the APAC region as a Senior Director.
👀 கவனிக்க வேண்டியவை
Investors should monitor the transition of leadership in the Health Care category and its potential impact on the company's performance. No immediate action is required.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
